Search Results - "Prat, Aleix"

Dissecting the biological heterogeneity of HER2-positive breast cancer by Schettini, Francesco, Prat, Aleix

“…HER2-positive (HER2+) breast cancer (BC) is a heterogenous and multifaceted disease, with interesting therapeutic implications. First, all intrinsic molecular…”
Get full text

Deconstructing the molecular portraits of breast cancer by Prat, Aleix, Perou, Charles M.

“…Breast cancer is a heterogeneous disease in terms of histology, therapeutic response, dissemination patterns to distant sites, and patient outcomes. Global…”
Get full text

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma by Prat, Aleix, Navarro, Alejandro, Paré, Laia, Reguart, Noemí, Galván, Patricia, Pascual, Tomás, Martínez, Alex, Nuciforo, Paolo, Comerma, Laura, Alos, Llucia, Pardo, Nuria, Cedrés, Susana, Fan, Cheng, Parker, Joel S, Gaba, Lydia, Victoria, Iván, Viñolas, Nuria, Vivancos, Ana, Arance, Ana, Felip, Enriqueta

“…Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a variety of solid tumors, but most patients exhibit partial or…”
Get full text

Immune-related adverse events of checkpoint inhibitors by Ramos-Casals, Manuel, Brahmer, Julie R., Callahan, Margaret K., Flores-Chávez, Alejandra, Keegan, Niamh, Khamashta, Munther A., Lambotte, Olivier, Mariette, Xavier, Prat, Aleix, Suárez-Almazor, Maria E.

“…Cancer immunotherapies have changed the landscape of cancer treatment during the past few decades. Among them, immune checkpoint inhibitors, which target PD-1,…”
Get full text

New anti-HER2 agents for brain metastasis: histology-agnostic weapons? by Tarantino, Paolo, Prat, Aleix, Curigliano, Giuseppe

“…Besides predicting responsiveness to anti-HER2 agents, HER2 aberrations are associated with a high incidence of central nervous system (CNS) metastasis across…”
Get full text

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial by Llombart-Cussac, Antonio, MD, Cortés, Javier, MD, Paré, Laia, PhD, Galván, Patricia, BS, Bermejo, Begoña, MD, Martínez, Noelia, MD, Vidal, Maria, MD, Pernas, Sònia, MD, López, Rafael, MD, Muñoz, Montserrat, MD, Nuciforo, Paolo, MD, Morales, Serafín, MD, Oliveira, Mafalda, MD, de la Peña, Lorena, PhD, Peláez, Alexandra, MD, Prat, Aleix, Dr

“…Summary Background HER2-positive breast cancer consists of four intrinsic molecular subtypes—luminal A, luminal B, HER2-enriched, and basal-like—and a…”
Get full text

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study by Rugo, Hope S, Lerebours, Florence, Ciruelos, Eva, Drullinsky, Pamela, Ruiz-Borrego, Manuel, Neven, Patrick, Park, Yeon Hee, Prat, Aleix, Bachelot, Thomas, Juric, Dejan, Turner, Nicholas, Sophos, Nickolas, Zarate, Juan Pablo, Arce, Christina, Shen, Yu-Ming, Turner, Stuart, Kanakamedala, Hemanth, Hsu, Wei-Chun, Chia, Stephen

“…Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced…”
Get full text

Clinical implications of the intrinsic molecular subtypes of breast cancer by Prat, Aleix, Pineda, Estela, Adamo, Barbara, Galván, Patricia, Fernández, Aranzazu, Gaba, Lydia, Díez, Marc, Viladot, Margarita, Arance, Ana, Muñoz, Montserrat

“…Abstract Gene-expression profiling has had a considerable impact on our understanding of breast cancer biology. During the last 15 years, 5 intrinsic molecular…”
Get full text

Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer by Gendoo, Deena M A, Ratanasirigulchai, Natchar, Schröder, Markus S, Paré, Laia, Parker, Joel S, Prat, Aleix, Haibe-Kains, Benjamin

“…Breast cancer is one of the most frequent cancers among women. Extensive studies into the molecular heterogeneity of breast cancer have produced a plethora of…”
Get full text

Frequency and spectrum of PIK3CA somatic mutations in breast cancer by Martínez-Sáez, Olga, Chic, Nuria, Pascual, Tomás, Adamo, Barbara, Vidal, Maria, González-Farré, Blanca, Sanfeliu, Esther, Schettini, Francesco, Conte, Benedetta, Brasó-Maristany, Fara, Rodríguez, Adela, Martínez, Débora, Galván, Patricia, Rodríguez, Ana Belén, Martinez, Antonio, Muñoz, Montserrat, Prat, Aleix

“…The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced…”
Get full text

Practical implications of gene-expression-based assays for breast oncologists by Prat, Aleix, Ellis, Matthew J., Perou, Charles M.

“…Gene-expression profiling has led to the development of signatures designed to predict survival and treatment response in patients with breast cancer. In this…”
Get full text

Biomarkers of immunotherapy response in breast cancer beyond PD-L1 by Chic, Nuria, Brasó-Maristany, Fara, Prat, Aleix

“…Immune checkpoint inhibitors have modified the treatment algorithm in a variety of cancer types, including breast cancer. Nevertheless, optimal selection of…”
Get full text

Molecular Characterization of Basal‐Like and Non‐Basal‐Like Triple‐Negative Breast Cancer by Prat, Aleix, Adamo, Barbara, Cheang, Maggie C.U., Anders, Carey K., Carey, Lisa A., Perou, Charles M.

“…Learning Objectives Contrast the definitions of TN and basal‐like. Describe the undistinguishable global gene expression patterns of non‐basal‐like TN tumors…”
Get full text

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer by Prat, Aleix, Parker, Joel S, Karginova, Olga, Fan, Cheng, Livasy, Chad, Herschkowitz, Jason I, He, Xiaping, Perou, Charles M

“…In breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which…”
Get full text

Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer by PRAT, Aleix, CHEANG, Maggie Chon U, PEROU, Charles M, MARTIN, Miguel, PARKER, Joel S, CARRASCO, Eva, CABALLERO, Rosalia, TYLDESLEY, Scott, GELMON, Karen, BERNARD, Philip S, NIELSEN, Torsten O

“…Current immunohistochemical (IHC)-based definitions of luminal A and B breast cancers are imperfect when compared with multigene expression-based assays. In…”
Get full text

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 by ELLIS, Matthew J, SUMAN, Vera J, ESSERMAN, Laura J, UNZEITIG, Gary W, MARGENTHALER, Julie, BABIERA, Gildy V, KELLY MARCOM, P, GUENTHER, Joseph M, WATSON, Mark A, LEITCH, Marilyn, HUNT, Kelly, OLSON, John A, HOOG, Jeremy, LI LIN, SNIDER, Jacqueline, PRAT, Aleix, PARKER, Joel S, JINGQIN LUO, DESCHRYVER, Katherine, CRAIG ALLRED, D

“…Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-positive breast cancer. To study this…”
Get full text

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis by Giuliano, Mario, MD, Schettini, Francesco, MD, Rognoni, Carla, PhD, Milani, Manuela, MD, Jerusalem, Guy, Prof, Bachelot, Thomas, MD, De Laurentiis, Michelino, MD, Thomas, Guglielmo, MD, De Placido, Pietro, MD, Arpino, Grazia, MD, De Placido, Sabino, Prof, Cristofanilli, Massimo, MD, Giordano, Antonio, MD, Puglisi, Fabio, MD, Pistilli, Barbara, MD, Prat, Aleix, MD, Del Mastro, Lucia, MD, Venturini, Sergio, PhD, Generali, Daniele, MD

“…SummaryBackgroundAlthough international guidelines support the administration of hormone therapies with or without targeted therapies in postmenopausal women…”
Get full text

miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway by Samaeekia, Ravand, Adorno-Cruz, Valery, Bockhorn, Jessica, Chang, Ya-Fang, Huang, Simo, Prat, Aleix, Ha, Nahun, Kibria, Golam, Huo, Dezheng, Zheng, Hui, Dalton, Rachel, Wang, Yuhao, Moskalenko, Grigoriy Y, Liu, Huiping

“…Effective targeting of cancer stem cells is necessary and important for eradicating cancer and reducing metastasis-related mortality. Understanding of cancer…”
Get full text

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer by Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, Prat, Aleix

“…Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of…”
Get full text

The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment by Skibinski, Adam, Breindel, Jerrica L, Prat, Aleix, Galván, Patricia, Smith, Elizabeth, Rolfs, Andreas, Gupta, Piyush B, LaBaer, Joshua, Kuperwasser, Charlotte

“…Lineage-committed cells of many tissues exhibit substantial plasticity in contexts such as wound healing and tumorigenesis, but the regulation of this process…”
Get full text